biovie inc. (otc pink: bivi) is developing novel drug therapies for life-threatening complications of chronic liver disease. our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, nash (non-alcoholic steatohepatitis), or alcoholism. ascites affects about 100,000 americans and carries an estimated 40% mortality rate within two years of being diagnosed. the company’s new drug candidate biv201 is about to enter a phase 2 clinical trial in the us. it’s based on a drug (terlipressin) not yet available in the us, but approved in about 40 countries for treating related complications of liver cirrhosis. the fda has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has orphan drug status. biovie has attracted funding from strategic investors including aspire capital, cuong do, the global strategy lead for samsung, and hari kumar, founder of adheron therapeutics which he sold to roche fo
Company profile
Ticker
BIVI
Exchange
Website
CEO
Terren S. Peizer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NANOANTIBIOTICS, INC.
SEC CIK
BIVI stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Apr 24
8-K
BioVie Announces Pipeline Update and Near-Term Clinical Priorities
11 Mar 24
8-K
BioVie Inc. Announces Closing of Public Offering
6 Mar 24
8-K/A
Financial Statements and Exhibits
4 Mar 24
424B5
Prospectus supplement for primary offering
4 Mar 24
8-K
BioVie Inc. Announces Proposed Public Offering of Common Stock
4 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
8-K
Other Events
1 Mar 24
10-Q
2023 Q2
Quarterly report
12 Feb 24
8-K
Other Events
25 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.21 mm | 21.21 mm | 21.21 mm | 21.21 mm | 21.21 mm | 21.21 mm |
Cash burn (monthly) | (no burn) | 1.35 k | 3.63 mm | 3.93 mm | 4.06 mm | 3.60 mm |
Cash used (since last report) | n/a | 9.24 k | 24.73 mm | 26.79 mm | 27.69 mm | 24.56 mm |
Cash remaining | n/a | 21.21 mm | -3.51 mm | -5.57 mm | -6.47 mm | -3.35 mm |
Runway (months of cash) | n/a | 15661.3 | -1.0 | -1.4 | -1.6 | -0.9 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 54 |
Opened positions | 19 |
Closed positions | 12 |
Increased positions | 19 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 8.49 bn |
Total shares | 51.86 mm |
Total puts | 29.10 k |
Total calls | 126.30 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Acuitas | 30.44 mm | $248.96 mm |
Peizer Terren S | 19.53 mm | $290.41 mm |
Ikarian Capital | 448.56 k | $1.93 bn |
Millennium Management | 334.72 k | $1.44 bn |
Vanguard | 178.76 k | $770.47 mm |
Geode Capital Management | 151.48 k | $652.86 mm |
BLK Blackrock | 92.58 k | $399.03 mm |
Boothbay Fund Management | 91.73 k | $395.35 mm |
STT State Street | 82.37 k | $355.01 mm |
Nuveen Asset Management | 72.60 k | $312.89 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Cuong V Do | Common stock | Buy | Acquire P | Yes | No | 0 | 10,000 | 0.00 | 435,854 |
4 Mar 24 | Cuong V Do | Warrants Common Stock | Buy | Acquire P | Yes | No | 1.5 | 5,000 | 7.50 k | 5,000 |
11 Dec 23 | Joanne Wendy Kim | Common Stock | Grant | Acquire A | No | No | 0 | 5,000 | 0.00 | 44,148 |
30 Nov 23 | Cuong V Do | Common stock | Buy | Acquire P | No | No | 1.78 | 10,000 | 17.80 k | 68,759 |
9 Nov 23 | Michael Edward Sherman | Stock Option Common Stock | Grant | Acquire A | No | No | 3.01 | 89,750 | 270.15 k | 89,750 |
9 Nov 23 | Berman Richard J | Common Stock | Grant | Acquire A | No | No | 0 | 51,830 | 0.00 | 69,235 |
News
BioVie To Present Data Showing How NE3107 Potentially Restores Homeostasis Via Specific Genes Associated With Dementia, Metabolism, And Inflammation
18 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
15 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
1 Apr 24
Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher
4 Mar 24
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
4 Mar 24
Press releases
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
12 Apr 24
Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation
26 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines – BIVI
23 Mar 24
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie
19 Mar 24
BIVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioVie Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
19 Mar 24